Symbol | Exchange | Currency |
|---|
Allogene Therapeutics (ALLO)perks up 5% premarketafterannouncingthat the FDA has granted Fast Track designation to ALLO-605, the next-generation AlloCAR T therapy targeting BCMA...
Phase 1 IGNITE Dose Escalation Trial of ALLO-605 Initiated in Q2 2021ALLO-605 is the Third Prong of the Company's Clinical Strategy to Target BCMA for the Treatment of Multiple...
With the newly-announced leadership change, Allogene Therapeutics is trading higher while Jefferies assumes coverage of the stock with a buy rating
Gilead Sciences’ GILD Kite announced positive top-line results from the primary analysis of the global phase III multicenter study, ZUMA-7.ZUMA-7 evaluated a one-time...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Buy | Sell | Sell |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Sell | Strong Sell |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,721.40 | 2,765.00 | 2,706.70 | +83.4 | +3.16% | 3.63M | NASDAQ | |||
| 373.58 | 377.54 | 367.00 | +5.77 | +1.57% | 16.31M | NASDAQ | |||
| 194.95 | 196.40 | 189.76 | +8.88 | +4.77% | 27.71M | NYSE | |||
| 53.13 | 53.92 | 52.94 | -0.05 | -0.09% | 18.98M | NASDAQ | |||
| 120.68 | 121.07 | 119.33 | +0.87 | +0.73% | 1.92M | NYSE | |||
| 194.70 | 196.46 | 189.95 | +2.62 | +1.36% | 15.13M | NASDAQ | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 43.48 | 43.74 | 42.26 | +1.38 | +3.27% | 38.23M | NYSE | |||
| 142.46 | 142.48 | 140.15 | +1.53 | +1.09% | 4.37M | NASDAQ | |||
| 21.10 | 21.25 | 20.91 | +0.11 | +0.52% | 7.60M | NYSE | |||
| 53.84 | 53.92 | 53.02 | +0.24 | +0.45% | 97.67K | NYSE | |||
| 41.41 | 41.87 | 39.80 | +2.05 | +5.21% | 51.24M | NYSE | |||
| 198.48 | 200.19 | 198.10 | -1.99 | -0.99% | 1.06M | NYSE | |||
| 61.10 | 61.55 | 60.43 | -0.06 | -0.10% | 710.67K | NYSE | |||
| 13.13 | 13.25 | 12.91 | +0.18 | +1.39% | 1.82M | NYSE |
Allogene Therapeutics, Inc. is a clinical stage immuno-oncology company. The Company is focused on developing and commercializing of allogeneic T cell therapies for the treatment of cancer. It is involved in developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and T cell manufacturing technologies. Its T cell product candidates are designed to target and kill cancer cells. Its product candidate includes UCART19, ALLO-501, ALLO-715 and ALLO-647. The Company’s UCART19 is an allogeneic CAR T cell therapy that targets CD19. The Company’s ALLO-501 is an allogeneic anti-CD19 CAR T cell product candidate, which is designed for the treatment of patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL). The Company’s ALLO-715 targets B-cell maturation antigen (BCMA) for the treatment of patients with R/R multiple myeloma.
